More on SAGE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $5.47 |
|
|||
| Open | $5.47 | ||||
| 52 Wk High | $62.64 | ||||
| 52 Wk Low | $26.28 | ||||
| Day High | $5.47 | ||||
| Day Low | $5.47 | ||||
| P/E | N/A | ||||
| EPS | $-0.94 | ||||
| Volume | 1 | ||||
- Form 8-K Sage Therapeutics, Inc. For: Nov 22
- Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
- Sage Therapeutics (SAGE) PT Lowered to $9 at TD Cowen
- RBC Capital Upgrades Sage Therapeutics (SAGE) to Sector Perform
- Form 8-K Sage Therapeutics, Inc. For: Nov 20
- SAGE Therapeutics (SAGE) Reports Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor
- Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
- Form SC 13G/A Sage Therapeutics, Inc. Filed by: BB BIOTECH AG
- Form 4 Sage Therapeutics, Inc. For: Nov 01 Filed by: Benecchi Christopher
- Form SC 13G/A Sage Therapeutics, Inc. Filed by: VANGUARD GROUP INC
Entities mentioned with SAGE
- FDA | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Goldman Sachs | View Related Stories »
- Twitter | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
